Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of DB289 versus pentamidine for first-stage human African trypanosomiasis
ISRCTN85534673Phase 3Completed
- Sponsor
- Immtech Pharmaceuticals, Inc.
- Start
- Jul 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial in African trypanosomiasis (HAT) comparing DB289 with Pentamidine (2 arms). Primary endpoint: Combined clinical and parasitological cure at 12 months. Started Jul 2005; status: completed.
02
Drugs
pafuramidinepentamidine
03
Conditions
African trypanosomiasis (HAT)
Beyond the preview
Go deeper on ISRCTN85534673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85534673.